Current Opinion in Oncology 2000, 12:368–377.PubMed 59. Reubi JC: A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth. Acta Endocrinol (Copenh) 1985, 109:108–114. 60. Scarpignato C, Pelosini I: Somatostatin analogs for cancer treatment and diagnosis: an overview.

Chemotherapy 2001, 47:1–29.PubMed 61. Imam H, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E, Oberg K: Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol 1997, 36:607–614.PubMed 62. Eriksson B, Renstrup J, Imam H, Oberg K: High-dose treatment with lanreotide of patients with advanced https://www.selleckchem.com/products/3-deazaneplanocin-a-dznep.html neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997, 8:1041–1044.PubMed 63. Faiss S, Räth Cetuximab purchase U, Mansmann U, Caird D, Clemens N, Riecken EO, Wiedenmann B: Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 1999, 60:469–476.PubMed 64. Lawnicka H, Stepieñ H, Wyczółkowska

J, Kolago B, Kunert-Radek J, Komorowski J: Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochem Biophys Res Commun 2000, 268:567–571.PubMed 65. Treiber G, Wex T, Röcken C, Fostitsch P, Malfertheiner P: Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2006, 132:699–708.PubMed 66. Dimitroulopoulos

D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D, Paraskevas E: Long acting octreotide in the treatment of advanced hepatocellular cancer and ioxilan overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol 2007, 13:3164–3170.PubMed 67. Lamberts SW, Krenning EP, Reubi JC: The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991, 12:450–482.PubMed 68. Bousquet C, Puente E, Buscail L, Vaysse N, Susini C: Antiproliferative effect of somatostatin and analogs. Chemotherapy 2001, 47:30–39.PubMed 69. Danesi R, Agen C, Benelli U, Paolo AD, Nardini D, Bocci G, Basolo F, Campagni A, Tacca MD: Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201–995). Clin Cancer Res 1997, 3:265–272.PubMed 70. Woltering EA, Watson JC, Alperin-Lea RC, Sharma C, Keenan E, Kurozawa D, Barrie R: Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs 1997, 15:77–86.PubMed 71. Anthony L, Johnson D, Hande K, Shaff M, Winn S, Krozely M, Oates J: Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 1993, 32:217–223.PubMed 72. Kvols LK, Woltering EA: Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. Anticancer Drugs 2006, 17:601–608.PubMed 73.